Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Launched by FRED HUTCHINSON CANCER CENTER · Jun 11, 2020

Keywords

ClinConnect Summary

The PQRST Study is a clinical trial designed to help doctors understand how well different treatments work for patients with chronic graft-versus-host disease (cGVHD). cGVHD is a condition that can occur after a stem cell transplant, where the new immune cells attack the patient's body. In this study, researchers will collect clinical data and blood samples from patients who are starting their first or second treatment for cGVHD. By analyzing this information, the goal is to find patterns that might predict how well a patient will respond to their treatment.

To participate in this trial, patients need to have had a stem cell transplant and should not have any ongoing cancers. They must be willing to visit the transplant center for evaluations at the start of treatment and again at several points afterward. The study is open to adults aged 65 and older, regardless of gender. Participants will play an important role in helping improve treatment strategies for cGVHD, and their involvement could lead to better outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults age 18 or older
• • Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
• • No evidence of persistent or progressive malignancy at the time of enrollment
• • Agrees to be evaluated at the transplant center before a new line of treatment is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
• • Signed, informed consent
• Exclusion Criteria:
• • Inability to comply with study procedures
• • Uncontrolled psychiatric disorder
• • Anticipated survival \< 6 months